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The Hundred Person Wellness Project (HPWP) is a 10-month pilot study of 100 ‘well’ individuals where integrated
data from whole-genome sequencing, gut microbiome, clinical laboratory tests and quantified self measures from
each individual are used to provide actionable results for health coaching with the goal of optimizing wellness and
minimizing disease. In a commentary in BMC Medicine, Diamandis argues that HPWP and similar projects will likely
result in ‘unnecessary and potential harmful over-testing’. We argue that this new approach will ultimately lead to
lower costs, better healthcare, innovation and economic growth. The central points of the HPWP are: 1) it is focused
on optimizing wellness through longitudinal data collection, integration and mining of individual data clouds, enabling
development of predictive models of wellness and disease that will reveal actionable possibilities; and 2) by extending
this study to 100,000 well people, we will establish multiparameter, quantifiable wellness metrics and identify markers for
wellness to early disease transitions for most common diseases, which will ultimately allow earlier disease intervention,
eventually transitioning the individual early on from a disease back to a wellness trajectory.
Please see related commentary: http://dx.doi.org/10.1186/s12916-014-0239-6.
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In early 2014, our team at the Institute for Systems Biol-
ogy initiated a 10-month pilot study called the Hundred
Person Wellness Project (HPWP). Ultimately, using les-
sons gleaned from this pilot study, our goal is to scale the
project up to 100,000 individuals – a ‘Framingham-like’
study for the digital age. The HPWP is the first real-world
test of the ‘P4 medicine’ paradigm – that is, using a sys-
tems approach to ultimately transform healthcare such
that it is ‘predictive, preventive, personalized and partici-
patory (P4) [1,2].
In the accompanying commentary, Prof. Diamandis
raises concerns about projects such as the HPWP, which
he equates to ‘population screening’ for disease, using
examples from cancer screening to elucidate his point
[3]. We fundamentally disagree with the characterization
of the HPWP as population screening, as well as with* Correspondence: lee.hood@systemsbiology.org
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tial ‘harms.’ Importantly, we believe evaluating the actual
outcomes of the pilot program will be far superior to
supposition of harms. The three primary goals of the
HPWP are:
1. To test the P4 paradigm in practice to demonstrate
its effectiveness;
2. To gather dynamic, longitudinal data to create and
validate proposed wellness metrics and demonstrate
that their actionability creates an opportunity for the
participant to optimize their wellness and for the
health system to focus on identifying early disease
transitions and reversing or at least mitigating them;
and
3. To develop a framework for scaling these findings
and to demonstrate cost effectiveness,
methodologies for application in the real world and
participant-centric management (rather than just
health system management) of individual health.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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There is widespread agreement that our current system of
healthcare – which is ‘disease-centric’ and reactive – is
not sustainable. The costs associated with treating the ris-
ing prevalence of chronic diseases such as Type 2 diabetes,
Alzheimer’s, cardiovascular disease, and cancer have been
predicted to bankrupt countries unless a very different
approach to healthcare is adopted. The convergence of
systems approaches to disease, new measurement and
visualization technologies, and new computational and
mathematical tools allows for the potential of P4 medi-
cine – which is cost-effective and increasingly focused
on wellness.
While wellness and prevention may have great concep-
tual appeal, there are relatively few widely-accepted, quan-
tifiable metrics to define ‘wellness’. Many individuals who
report that they feel reasonable ‘well’, may, in fact, have
multiple abnormalities in biochemical markers reflecting
organ and system dysfunction, nutritional status or other
health risk, which we have observed repeatedly in the
HPWP. Thus, there is a real need to define and systemize
quantifiable wellness metrics, with longitudinal data that
supports their validity and clinical usefulness. Moreover,
we believe that we can eventually generate a multiparame-
ter metric for wellness – by employing data from individ-
uals exhibiting wellness over an extended period of time.
It will reflect both the psychological and physiological as-
pects of wellness, thus quantifying wellness – a concept to
date that has been defined in vague and ambiguous terms.
Until recently, the potential benefits of P4 medicine
were largely hypothetical [3]. The HPWP, and its subse-
quent scale-up to 100,000 individuals, will provide the sci-
entific and logistical framework to test these hypotheses in
a real-world setting [1]. Although the HPWP pilot project
is still ongoing, there have already been interesting discov-
eries, many actionable findings, a tendency for some indi-
viduals to take greater control of their own health, and
early validation that the promises of P4 medicine are likely
to be upheld.
In the HPWP, we are gathering data in four main areas:
1) whole genome sequencing; 2) clinical and functional la-
boratory testing (every three months); 3) gut microbiome
(every three months); and 4) quantified self and traits
(physical activity, sleep, weight, blood pressure, personality
and lifestyle factors, and so on). Once the results are
returned, health coaches work with participants on a
monthly basis to identify priority areas for lifestyle change
or make referrals to physicians if medical follow-up is war-
ranted. In addition to the data for which we are coaching,
we are measuring a variety of proteomic and metabolo-
mics markers as part of a scientific discovery effort.
Diamandis raises concerns about a number of poten-
tial harms that can result when asymptomatic individ-
uals are studied and characterized using a large numberof biometric variables, especially genetic variables [3].
Each of these concerns is addressed briefly below in the
context of the HPWP.Does screening asymptomatic individuals potentially
cause psychological distress?
There is a common myth that if a healthy individual re-
ceives information (especially genetic information) reveal-
ing increased risk for a disease that is not currently
treatable, it will lead to anxiety, depression or other psy-
chological distress. However, a fairly large body of litera-
ture contradicts this assumption. For example, Bloss et al.
[4] looked at the responses of more than 2,000 healthy
adults to direct-to-consumer genetic testing over one year
and found no overall increase in health-related anxiety,
with <3% of the sample reporting any degree of test-
related distress. Conversely, 62% perceived the testing to
be ‘of high personal utility’. Similarly, a meta-analysis of
studies where people were told their genetic risk for obes-
ity, heart disease, depression or diabetes revealed no im-
pact on individuals’ perceived control or ‘fatalism’ [5].
Perhaps most striking, Green and colleagues [6] analyzed
the psychological impact of receiving information on per-
sonal genetic risk for Alzheimer’s disease in individuals
with a family history of this currently untreatable disease.
They found no difference in anxiety or depression up to
one year post-testing in those who received genetic results
versus those who did not, regardless of whether they had
the high-risk allele or not. Thus, on the basis of current
evidence, one cannot argue that a positive finding in a
screening test causes psychological distress, regardless of
whether or not treatment or prevention is available. This
concern is particularly unlikely in the HPWP where only
actionable findings are being reported.False positives and negatives
It is inevitable that screening thousands of data points will
generate false positives, as well as false negatives, and we
take this concern seriously. One reason for the necessity
of conducting a project on a very large scale (that is, the
100 K project) is so that appropriate analytics and
methods development can be performed to improve the
reliability and reproducibility of results, reducing the
problem of false positives and negatives. Another key
approach that we are using in the HPWP is thoughtfully
tailored messaging and communications with participants
about the likelihood of false positives and negatives, so
that they can make well-informed decisions. Utilization of
health coaches, advised by physicians, to discuss study re-
sults and provide appropriate context about false positives
and negatives, particularly for newer technologies such as
gut microbiome and whole-genome sequencing, is an-
other essential element of our approach.
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Many experts have written about the challenge of com-
municating incidental findings. In the realm of genetic
screening, the American College of Medical Genetics has
issued a formal policy for incidental findings related to
certain single-gene disorders [7]. Lautenbach et al. [8]
provide a comprehensive overview of this area, pointing
out that in many cases communication of incidental gen-
etic findings actually leads to improved health behaviors
and greater patient engagement with the medical commu-
nity. Similarly, in the direct-to-consumer genetic study by
Bloss et al. [4], 36% of participants shared their genetic re-
sults with their physician, suggesting that fears of inciden-
tal findings leading to a flurry of medically unauthorized
tests or procedures are unfounded. In the context of the
HPWP, it is important to note that the project’s focus on
wellness means that many of the findings communicated
are actionable in terms of improvements to nutrition, ex-
ercise, stress management or compliance with existing
medical prescriptions. These actions are thus safe, gener-
ally low-cost and consistent with practices well known to
promote overall optimization of health and wellbeing.
Concerns about invasive treatments with serious side-
effects or harms are less of an issue when the focus is well-
ness rather than disease, and where those cases that could
potentially indicate disease are referred to a medical pro-
vider for actual diagnosis and follow up.Cost-effectiveness
One of the major concerns raised about projects like
HPWP that involve large numbers of ‘-omics’ measures is
the cost-effectiveness, which include the costs of the tests
themselves, the potential costs of additional medical care
if positive findings occur, and whether or not early inter-
vention is actually cost-saving. Regarding the costs of the
testing, there is no question that today’s costs are high.
However, costs are dropping rapidly and across the board
so that, in the future, the cost of doing these tests will
be dramatically lower. For example, today it costs from
$2,000 to $4,000 to determine a human genome se-
quence. In a five to eight year period it is likely this cost
will be reduced to close to $100 (more than an order of
magnitude decrease in cost). Likewise, we acknowledge
that there are potential increased short-term costs from
medical care that might be initiated due to findings in
the HPWP. Given that our focus is on wellness, though,
the frequency of needing additional medical follow up
is fairly low. To date in our project, we are only aware
of one instance where an individual required short-
term medical follow-up (for an elevated serum ferritin
level, which was ultimately diagnosed by the provider
as hemochromatosis) apart from routine physical exams
and follow ups.The power of integrated and longitudinal data
One of the key differentiators in projects like the HPWP
from standard population screening is the integration of
various types of data which provide a more comprehen-
sive assessment and, ultimately, more quantified metrics
of wellness and wellness-disease transitions. For example,
the MTHFR gene codes for an enzyme that plays an im-
portant role in processing amino acids and chemical reac-
tions involving the B-vitamin, folate. Individuals with
certain MTHFR variants have significantly reduced en-
zyme function which can lead to excess homocysteine in
the blood, a known independent risk factor for cardiovas-
cular disease: 1) with only genetic data available, an indi-
vidual could just be told whether or not they have
increased risk for abnormal folate metabolism and a likely
increased homocysteine level; or 2) with only laboratory
data available, we could tell the individual if their homo-
cysteine was elevated but we could not tell them why or
how to address it. With two integrated data types, we
could provide actionable recommendations that could in-
clude either a need for increased B-vitamin intake or no
need for dietary change. This example involves only two
types of data, but as the project expands and additional
bioinformatics reveal linkages between genetic, laboratory,
microbiome and quantified-self data, the ability to deeply
tailor and personalize actionable recommendations also
grows tremendously.
A second key differentiator from many population-
screening endeavors is the longitudinal nature of data
collection. Tracking biomarkers from multiple sources
(blood, urine, stool, and so on) in relation to environmen-
tal and lifestyle factors (physical activity, weight, stress,
and so on) every three to six months over many years will
enable the quantification of wellness with scientifically val-
idated metrics. Further, it will identify early transitions to
disease, in many cases at a stage when lower-cost inter-
ventions may still be effective or the disease can be de-
layed or even prevented.
Future direction and conclusions
The launch of the HPWP pilot study is an exciting step to-
ward a future of optimizing wellness and providing early
disease prevention – one that hopefully helps catalyze a
new era of medicine that is personalized, predictive, pre-
ventive and participatory.
We disagree with Prof. Diamandis’ characterization of
this project as ‘population screening’, which implies a dis-
ease focus rather than the actual wellness focus of our
project. On the contrary, there are broad potential benefits
to both our approach and our project goals – including
scientific discovery, healthcare cost containment, innova-
tion, optimization of individual health and wellbeing, and
democratization of healthcare – which far outweigh any
possible harms. We have shown that many of the feared
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sults or unnecessary medical treatments, seem unlikely
based on current research.
The ongoing interaction between participants and
health coach and each other through social networking
and community creates relationship-based accountability –
increasing motivation for long-term lifestyle change.
This is rarely, if ever, an outcome of population-based
screening for disease. The immediate feedback provided
through longitudinal testing multi-times per year fur-
ther enhances participants’ motivation and attention to
wellness and prevention. Although some biomarkers
take longer to improve than others, there are enough
that improve in the short-term due to modifications in
diet, and exercise and reduced stress, which reinforce
effective health behavior change.
As new technologies and computational approaches
emerge and test costs decrease dramatically – and the
interest of the general public in playing an active role in
their own health and wellness continues to increase – a
transformation in our approach to healthcare is inevitable.
Equally inevitable is some degree of fear and resistance
from those who are invested in maintaining the status
quo. This occurs during any significant paradigm shift.
We are convinced that the benefits of the P4 approach to
health will continue to become clear in the coming years
as our project grows in numbers and the scientific discov-
eries, along with individual success stories of optimizing
health and preventing disease, emerge.
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